Incretin-based therapies: mimetics versus protease inhibitors
- 31 August 2007
- journal article
- review article
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 18 (6) , 240-245
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006
- The biology of incretin hormonesCell Metabolism, 2006
- The [pre-] history of the incretin conceptRegulatory Peptides, 2005
- The Incretin Approach for Diabetes TreatmentDiabetes, 2004
- Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjectsRegulatory Peptides, 2003
- Role of the Vagus Nerve in Mediating Proximal Nutrient-Induced Glucagon-Like Peptide-1 SecretionEndocrinology, 1999
- Gastric emptying and release of incretin hormones after glucose ingestion in humans.Journal of Clinical Investigation, 1996
- Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loopEndocrinology, 1993
- Glucagon-like peptide-1(7–36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patternsJournal of Endocrinology, 1993
- Glucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and manEuropean Journal of Clinical Investigation, 1992